Zer, Alona
Tel Aviv University · Rabin Medical Center
4 papers on CoChatORCID 0000-0001-6597-5261
Most cited papers
- Verified
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
West, H., McCleod, M., Hussein, M., Morabito, A., Rittmeyer, A., Conter, H. J., Kopp, H.-G., Daniel, D., McCune, S., Mekhail, T., et al. (2019) · The Lancet Oncology
Lung Cancer Treatments and MutationsCancer Immunotherapy and Biomarkers
Cited by 1,662
- Verified
Role of Palliative Care in Adolescent and Young Adult Oncology
Wein, S., Pery, S., & Zer, A. (2010) · Journal of Clinical Oncology
Palliative and Oncologic CarePalliative Care and End-of-Life Issues
Cited by 105
- Verified
IMpower130: Progression-free survival (PFS) and safety analysis from a randomised phase III study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab (atezo) as first-line (1L) therapy in advanced non-squamous NSCLC
Cappuzzo, F., McCleod, M., Hussein, M., Morabito, A., Rittmeyer, A., Conter, H. J., Kopp, H.-G., Daniel, D., McCune, S., Mekhail, T., et al. (2018) · Annals of Oncology
Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations
Cited by 57
- Verified
Pooled analysis of the prognostic and predictive value of KRAS mutation status and mutation subtype in patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors
Zer, A., Ding, K., Lee, S. M., Goss, G. D., Seymour, L., Ellis, P. M., Hackshaw, A., Bradbury, P. A., Han, L., O’Callaghan, C. J., et al. (2016) · Journal of Thoracic Oncology
Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment
Cited by 56
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free